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Abstract
Background: Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by a broad
range of neoplasms to maintain telomere length, permitting uncontrolled replication during their progression. ALT
has been described in different types of sarcoma, but a comprehensive analysis of its clinical significance is still
lacking. Therefore, we provide here the first meta-analysis on this topic.
Methods: We searched SCOPUS and PubMed through July 2018 to identify all studies that investigated the prognostic
role of ALT in sarcomas. We considered the risk of death (risk ratio, RR) calculated as the number of death vs. total
participants during follow-up in ALT+ versus ALT- patients as the primary outcome. The secondary outcome was the
hazard ratio (HR), adjusted for the maximum number of covariates available, using ALT- patients as reference.
Results: Eight articles comprising a total of 551 patients with sarcomas (226 ALT+ and 325 ALT-) were selected. The
ALT+ group showed a higher mitotic count and a higher tumor grade compared with the ALT- group (p < 0.01).
Furthermore, we demonstrate a strong impact of ALT on survival. In fact, ALT+ patients showed a statistically
significant higher risk of death than ALT- patients, when also considering data from multivariate analyses (RR = 1.50;
95% CI: 1.15–1.96; p = 0.003; HR = 2.02; 95% CI: 1.22–3.38; p = 0.007).
Conclusions: Our results indicate that ALT is associated with an increased risk of death in patients with sarcoma. In
these neoplasms, ALT should be taken into account for a precise prognostic stratification and design of potential
therapeutic strategies.
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Background
In somatic cellular compartment, each round of cell div-
ision is accompanied by telomere shortening [1, 2]. This
process is physiologically due to the inability of somatic
cells to polymerize all DNA during replication. In cancer,
this same process is overcome by the cancer cells in order
to initiate and support cancer growth [3]. In fact, a hallmark
of cancer is its unlimited replicative capacity, which can be
achieved through the activation of so-called telomere
maintenance mechanisms [3]. In the majority of cancers,
telomere shortening is counterbalanced by the enzymatic
activity of telomerase, a DNA-polymerase that provides de
novo synthesis of telomeric DNA by reverse transcription
of a RNA template [4–6]. However, a subset of neoplasms,
mainly represented by sarcomas and gliomas, lacks tel-
omerase and therefore maintains telomere length through
a different telomerase-independent process, called alterna-
tive lengthening of telomeres (ALT) [7]. This mechanism
concerns the synthesis of new telomeric DNA on the basis
of a DNA template, where the telomere can either use
itself, a telomere on a sister chromatid or even another
chromosomes as the copy template [8, 9]. For this reason,
ALT cells are characterized by long and heterogeneous
telomeres and comprise sub-nuclear structures, such as
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APB (ALT-associated promyelocytic leukemia bodies) that
contain telomeric DNA, and telomere-specific binding
proteins, called TRF (terminal restriction fragments) [10].
Sarcomas represent a rare and heterogeneous group of
mesenchymal neoplasms, with different clinical manifes-
tations and biological behavior. A recently proposed
classification of these tumors distinguishes two classes of
sarcomas, one with simple karyotypes involving specific
genetic alterations, and one with complex and unbal-
anced karyotypes, usually involving non-specific genetic
abnormalities, including copy number alterations [11].
Despite such a complex molecular landscape, a relatively
common cytogenetic anomaly of sarcomas, represented
by ALT, has been demonstrated in both classes [12].
However, a comprehensive analysis of the clinical signifi-
cance of ALT for this kind of neoplasms is still lacking.
To this end, we assessed the prognostic role of ALT in
sarcomas by performing the first systematic review with
meta-analysis on this topic.
Methods
The systematic review adhered to the MOOSE guide-
lines [13] and the PRISMA statement [14], based on a
preset protocol (Additional file 1 Table S1).
Inclusion and exclusion criteria
Studies were considered eligible if they met the following
inclusion criteria: 1) involved a prospective cohort or
retrospective study design; 2) investigated sarcomas either
in general or a specific sarcoma subtype; 3) included a
genetically-demonstrated presence of ALT; 4) included a
comparison of prognostic factors among patients with ALT
(ALT+) vs. without ALT (ALT-); 5) included data on mor-
tality both overall and cancer-specific; and 6) the publica-
tion appeared in a peer-reviewed journal in the English
language. Exclusion criteria were: 1) no mention of sarcoma
of any subtype, 2) no mention of prognostic parameters in
the title/abstract; 3) only indirect analysis of ALT associated
alterations (e.g. mutational status of ALT-associated genes);
and 4) in vitro or animal studies. In the case of doubled co-
horts, the largest one was selected.
Data sources and literature search strategy
Two investigators (RTL, CL) independently searched the
PubMed, SCOPUS, EmBase and ISI databases up to July
17th 2018. The search terms included combinations of
the following keywords: (“alternative lengthening of telo-
meres”) AND (mortality OR mortalities OR fatality OR
fatalities OR death* OR survival OR prognosis OR “haz-
ard ratio” OR HR OR “relative risk” OR RR). All refer-
ences from all selected articles were also considered.
Study selection
Following the database searches outlined above, dupli-
cates were removed and two reviewers (RTL, AP) inde-
pendently reviewed both the titles and abstracts of all
the potentially eligible articles. The two authors applied
the eligibility criteria and considered the full texts. A
final list of articles was drawn up by consensus with a
third independent author (NV).
Data extraction
Two authors were involved in extracting the data into a
preset Excel database: one (AP) extracted the data from
the selected articles; the other (CL) independently vali-
dated the data. For each article, the following informa-
tion was extracted: authors; year of publication; country;
type of sarcoma; methods of ALT assessment; other
ALT-associated parameters that were included in the
studiesd; number of patients, together with their gender
and age, data on mitotic index, tumor grade, number of
adjustments in the case of multivariable analysis, mean
or median follow-up.
Outcomes
The primary outcome was represented by the number of
deaths after treatment during follow-up in ALT+ versus
ALT- patients (considering all-cause mortality and
cancer-specific mortality together). The secondary out-
come was represented by the hazard ratio (HR), adjusted
for the maximum number of covariates available, using
ALT- patients as the reference. Five-year follow-up data
were extracted, where available; otherwise, the maximum
reported follow-up was considered.
Study quality assessment
The Newcastle-Ottawa Scale (NOS) was used to evaluate
the quality of the studies [15]. This provides an assess-
ment of the methodological quality of observational
studies [16]. The studies were evaluated on the basis of
eight elements across three key areas: selection of partic-
ipants, comparability of participants, and outcomes. One
author (CL) designed and completed the NOS and each
study was attributed an overall score for methodological
quality of up to nine points.
Data synthesis and statistical analysis
All analyses were conducted using Comprehensive Meta-
Analysis v2 software (Biostat; Englewood, NJ, USA). In our
primary and secondary analyses, pooled RR and HR with
corresponding 95% confidence intervals (CI) were calcu-
lated for mortality, comparing ALT+ with ALT- cases using
DerSimonian-Laird random-effects models [17].
Heterogeneity across studies was assessed with I2
metric and chi square statistics [18]. A meta-regression
analysis was performed in cases of high heterogeneity
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(i.e., I2 ≥ 50%) [19]. Eventual outlier studies were re-
moved in a sensitivity analysis. Finally, we investigated
publication bias by visual inspection of funnel plots and
with the Egger bias test [20].
Results
Search results
The literature search identified a total of 371 unduplicated
articles, 345 of which were excluded after review of their
titles/abstracts, resulting in 26 articles eligible for full text
review. After application of our inclusion criteria, eight ar-
ticles, with a total of nine cohorts, were included in the
meta-analysis (Additional file 2: Figure S1) [21–28].
Characteristics of studies and patients
As shown in Additional file 3: Table S2, the 8 articles
selected for the meta-analysis included a total of 9 differ-
ent cohorts of patients comprising 551 patients with
sarcomas (226 ALT+ and 325 ALT-) with a median
follow-up period of 52.2 months (range: 28–92).
The ALT+ group had a statistically significant higher
mitotic count compared with the ALT- group (p =
0.0078, Fisher’s exact test), in addition to a statistically
significant higher tumor grade (p < 0.0001). The ALT+
group comprised a higher proportion of women than
ALT- (77% vs. 60%); ALT+ patients were also older than
ALT- (54.9 vs 50.9 years old), but these differences were
not statistically significant.
The median NOS score indicated the overall good quality
of the studies (median, 7 points; range, 6–9), with no man-
uscripts displaying a high risk of bias (Additional file 3:
Table S2 and Additional file 4: Table S3).
Two studies investigated the prognostic role of ALT in
liposarcoma [21, 24] and two others in leiomyosarcoma
[25, 27]; the remaining five cohorts investigated other
types of sarcoma (Additional file 3: Table S2). ALT status
was assessed by the evaluating APB in six cohorts (TRF
was also evaluated in two of these) and by fluorescent
in situ hybridization (FISH) in the remaining three
(Additional file 3: Table S2).
Risk ratio for survival
Table 1 shows the risk ratios estimated by ALT status.
Pooling the results from the 8 cohorts reporting RR
[24–30], we found that ALT+ patients had a statistically
significant higher risk of death than ALT- patients (RR =
1.50; 95% CI: 1.15–1.96; p = 0.003) (Fig. 1). The one
unique outlier-study, that investigated a cohort of osteo-
sarcoma patients [22], was removed in the sensitivity
analysis, and the RR was re-calculated. It maintained the
statistical significance, showing a similar value (RR =
1.48; 95% CI: 1.13–1.95; p = 0.001). No publication bias
emerged for this outcome (Egger’s test = 1.49 ± 0.95; p =
0.17), as also shown by the funnel plot (Additional file 5:
Figure S2A).
Hazard ratio for survival
Table 1 shows also the HR estimated by ALT status. In
the case of adjusted analysis, the median number of
adjustments was 2.25 (range 1–3) (Additional file 6:
Table S4). Pooling the results from the 6 cohorts reporting
HR adjusted for potential confounders [21, 22, 25, 26, 28],
we found that ALT+ doubled the risk of death, with a
statistically significant value (HR = 2.02; 95% CI: 1.22–3.38;
p = 0.07). Similar to the sensitivity analysis conducted for
RR, we removed the same unique outlier study on osteosar-
coma [22]: the recalculated HR maintained statistical sig-
nificance, showing a slightly higher value (HR = 2.08; 95 CI:
1.18–3.66; p = 0.01). No publication bias emerged either for
this outcome (Egger’s test = 1.40 ± 2.26; p = 0.57), as also
shown by the funnel plot (Additional file 5: Figure S2B).
Meta-regression analyses
Only risk ratio of survival demonstrated high heterogen-
eity (I2 = 53%). We therefore performed a meta-regression
analysis for this outcome, searching for potential modera-
tors of the heterogeneity, and found that it may be partly
explained by the presence of different sarcoma histotypes.
In fact, a sub-analysis considering only leiomyosarcoma
showed a drastic reduction of heterogeneity (I2 = 0%),
while it remained high (I2 = 64%) when considering the
remaining studies altogether (all studies analyzing differ-
ent sarcoma types).
Discussion
In this study, we analyzed 9 different cohorts involving
551 patients with sarcomas. Of these, 226 were ALT+
while 325 were ALT-. Our findings indicate that activation
of the ALT mechanism is associated with an increased risk
of mortality in this type of tumor. Noticeably, this associ-
ation is reinforced when considering HR adjusted for po-
tential confounders. Furthermore, no risk of publication
Table 1 Risk Ratio and Hazard Ratio for survival on the basis of ALT status
Parameter N Cohorts Risk Ratio (95% CI) p Value Heterogeneity (I2%); tau2 Egger Test (p value)
Survival 8 1.50 (1.15–1.96) 0.003 53%; 0.07 1.49 (0.17)
Parameter N Cohorts Hazard Ratio (95% CI) p Value Heterogeneity (I2); tau2 Egger Test (p value)
Survival 6 2.02 (1.22–3.38) 0.007 49.8%; 0.19 1.40 (0.57)
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bias was documented, highlighting the robustness of
the findings. Based on our results, the ALT mechanism
appears to have a strong clinical impact in sarcomas
(doubled risk of mortality, HR = 2.02). Given that this
meta-analysis pooled together the different risks of
mortality of several sarcoma types, the high statistical
significant values of ALT further highlight its widely ap-
plicable prognostic value.
ALT has been demonstrated to be an important bio-
logical process in different cancer types [7], and in par-
ticular neoplasms it has a strong prognostic significance.
For example, in neuroendocrine tumors of the pancreas
(PanNET), the activation of this mechanism is associated
with an increased risk of mortality and of distant metastasi-
zation, even in low-grade neoplasms [29–31]. Interestingly,
in pediatric malignant brain tumors, the presence of ALT
is associated with a better prognosis, above all in cases of
concomitant TP53 mutation [32]. The present study dem-
onstrates that ALT plays an important prognostic role in
sarcoma, as it is associated with an increased risk of death.
Given that ALT was associated with a higher mitotic count
and a higher tumor grade in our analysis, the fact that it
maintained its prognostic significance also when using data
from multivariable analysis (adjusted among others also for
tumor grade, Fig. 2, Additional file 6: Table S4) further
highlights its clinical importance. The one exception to the
poor prognostic value of ALT in the heterogeneous group
of sarcomas appears to be osteosarcoma. Although there
are few data upon which to draw definitive conclusions,
Sanders and colleagues suggested that patients with ALT+
osteosarcoma may have a diminished risk of tumor
recurrence [33]. While our meta-analysis demonstrated re-
liable results regarding the poor prognostic value of ALT in
soft tissue sarcoma, further studies are needed to advance
current knowledge about concerning ALTand prognosis.
The activation of the ALT mechanism has been also
shown to closely correlate with the mutational status of
the chromatin remodeling genes DAXX (death domain-as-
sociated protein) and ATRX (α-thalassemia/mental retard-
ation X-linked) in different malignancies, including
PanNET and pediatric glioblastoma [30, 31, 34–38].
DAXX and ATRX may be also mutated in different
types of sarcomas [12, 27, 39, 40]. These genes encode
nuclear proteins essential in regulating the deposition
of histone variant H3.3 during the assembly of pericen-
tromeric and telomeric chromatin [41]. DAXX/ATRX
mutations may be studied not only with molecular ana-
lysis but also with immunohistochemistry, representing
a widely-accepted surrogate of their mutational status,
that shows loss of the encoded proteins associated with
their mutations [30, 31]. In general, mutations affecting
DAXX are more common in PanNET [30, 31, 42],
whereas those affecting ATRX are markedly prominent
in sarcomas [39, 40]. While in PanNET DAXX/ATRX
immunohistochemical loss is absolutely associated with
ALT+, the situation appears more complex in sarcomas.
In fact, only about 50% of ALT+ leiomyosarcomas and
pleomorphic liposarcomas are also ATRX deficient [24, 25];
at the same time ALT+ appears to be highly correlated with
ATRX loss in angiosarcomas and dedifferentiated liposarco-
mas [24, 43]. Therefore, in the heterogeneous tumor group
of sarcomas, other biological (both genetic and epigenetic)
Fig. 1 Forest plot of risk ratio for mortality in sarcoma patients
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changes (still largely unknown) may concur in activating
ALT and determining the so-called “ALT phenotype”. In
the complex background of ALT-DAXX/ATRX interactions,
our findings concerning the reliability of ALT as a strong
prognostic moderator appear of greater importance.
The evaluation of ALT also has potential implications
for targeted therapeutic strategies. Recent evidence has
indicated that the inhibition of the protein kinase ATR
(ataxia telangiectasia and Rad3-related protein), a crucial
regulator of DNA recombination, can disrupt ALT by
triggering chromosome fragmentation and apoptosis in
ALT cells [43]. Cell death induced by ATR inhibition is
highly selective for ALT+ cells, suggesting ATR inhibi-
tors as potentially useful in the treatment of ALT+ can-
cers [9, 44–46]. Notably, some ATR inhibitors have been
already tested in vivo for cancer treatment with encour-
aging results [47–49]. As we have highlighted that the
activation of this mechanism has a poor prognostic im-
pact in sarcomas, this potential therapeutic approach
could also be explored in this tumor category. The inte-
gration of ALT status in pathology reports may therefore
provide useful prognostic and therapeutic information
for sarcomas as part of a next-generation histopatho-
logical approach [50].
This analysis presents results based on the review of a
number of studies that do, however, have some limitations
worth considering. The first concerns the overall sample
size but this is, in part, due to the rarity of the tumor type.
That said, the presence of different sarcoma types in the
analysis adds some level of reliability. Additionally, data
regarding possible co-morbidities such as cardiovascular
diseases were not reported in the studies, although these
are known to play an important role in the prognosis of
these cancer patients. Finally, the different biological
behavior of ALT in osteosarcoma [33] compared to all
other sarcoma sub-types requires additional data on sur-
vival to further explore this particular aspect.
Conclusions
In conclusion, our results indicate that ALT+ is associ-
ated with an increased risk of death in patients with soft
tissue sarcoma, even after adjusting for potential con-
founders. As this mechanism is present in a significant
proportion of this tumor type, its determination appears
of primary importance for a correct prognostic stratifica-
tion of such patients and for designing future thera-
peutic strategies.
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Fig. 2 Forest plot of hazard ratio for mortality in sarcoma patients
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